Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration 21 CFR Parts 510, 520, 522, 524, 556, and 558
[Docket No. FDA-2018-N-0002]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Final rule; technical amendments.
 SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during April, May, and June 2018. FDA is informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to make technical amendments to improve the accuracy and readability of the regulations.
 DATES: This rule is effective December 18, 2018.
 FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, 
                        *george.haibel@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION:  I. Approval Actions FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during April, May, and June 2018, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the office of the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the internet may obtain these documents at the CVM FOIA Electronic Reading Room: 
                    *https://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm.*
                     Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: 
                    *https://www.fda.gov/​AnimalVeterinary/​Products/​ApprovedAnimalDrugProducts/​default.htm.* Table 1—Original and Supplemental NADAs and ANADAs Approved During April, May, and June 2018
Approval date
File 
                             No.
Sponsor
Product name
Species
Effect of the action
Public 
                             documentsMay 4, 2018
141-481
Kindred Biosciences, Inc., 1555 Bayshore Hwy., Suite 200, Burlingame, CA 94010
MIRATAZ (mirtazapine transdermal ointment)
Cats
Original approval for the management of weight loss in cats
FOI Summary.May 15, 2018
141-501
Boehringer Ingelheim Vetmedica, Inc., 2621 North Belt Hwy., St. Joseph, MO 64506-2002
SEMINTRA (telmisartan oral solution)
Cats
Original approval for the control of systemic hypertension in cats
FOI Summary.May 25, 2018
141-063
Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940
NUFLOR (florfenicol), Injectable Solution
Cattle
Supplemental approval to provide human food safety information for the use of the inactive ingredient
                            *n*
                            -methyl-2-pyrrolidone (NMP)
FOI Summary.May 31, 2018
141-495
Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140
INTEPRITY (avilamycin) and BIO-COX (salinomycin sodium) Type C medicated feeds
Chickens
Original approval for the prevention of mortality caused by necrotic enteritis and for the prevention of coccidiosis in broiler chickens
FOI Summary.June 6, 2018
141-342
Jurox Pty. Ltd., 85 Gardiner Rd., Rutherford, NSW 2320, Australia
ALFAXAN (alfaxalone), Injectable Solution
Dogs and cats
Supplemental approval providing for addition of preservatives and use of a multidose vial
FOI Summary.June 14, 2018
098-379
Merial, Inc., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640
CYSTORELIN (gonadorelin), Injectable Solution
Cattle
Supplemental approval for use with cloprostenol sodium to synchronize estrous cycles to allow for fixed-time artificial insemination (FTAI) in lactating dairy cows and beef cows
FOI Summary, EA/FONSI.11
                         The Agency has carefully considered an environmental assessment (EA) of the potential environmental impact of this action and has made a finding of no significant impact (FONSI).
 II. Technical Amendments With the approval of NADA 141-481, Kindred Biosciences, Inc. is now the sponsor of an approved application. Accordingly, we are amending § 510.600(c) to add the name, address, and drug labeler code of this sponsor. Piramal Healthcare Ltd., Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India, has informed FDA that it has changed its name and address to Piramal Enterprises Ltd., Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Mag Kurla (West), Mumbai, 400070, India. We are amending § 510.600(c) to reflect this change. We are also making technical amendments to update the scientific name of a pathogenic bacterium and to accurately list the concentrations of active ingredients in an otic dosage form new animal drug. We are also making a technical amendment to correct the sponsor of epsiprantel tablets. These actions are being taken to improve the accuracy of the regulations. In addition, we are reformatting the regulations to create a tabular display of 
                    ( print page 64739)
                    the approved uses of narasin and a separate section for uses of a fixed-ratio, combination drug Type A medicated article containing narasin and nicarbazin. These actions are being taken to improve the readability, consistency, and accuracy of the regulations. III. Legal Authority This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360b(i)), which requires 
                    **Federal Register**
                     publication of “notice[s] . . . effective as a regulation,” of the conditions of use of approved new animal drugs. This rule sets forth technical amendments to the regulations to codify recent actions on approved new animal drug applications and corrections to improve the accuracy of the regulations, and as such does not impose any burden on regulated entities. Although denominated a rule pursuant to the FD&C Act, this document does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a “rule of particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. Likewise, this is not a rule subject to Executive Order 12866, which defines a rule as “an agency statement of general applicability and future effect, which the agency intends to have the force and effect of law, that is designed to implement, interpret, or prescribe law or policy or to describe the procedure or practice requirements of an agency.” List of Subjects 21 CFR Part 510 Administrative practice and procedure
Animal drugs
Labeling
Reporting and recordkeeping requirements 21 CFR Parts 520, 522, and 524 Animal drugs 21 CFR Part 556 Animal drugs
Foods 21 CFR Part 558 Animal drugs
Animal feeds
 Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 510, 520, 522, 524, 556, and 558 are amended as follows: PART 510—NEW ANIMAL DRUGS
 1.The authority citation for part 510 continues to read as follows: Authority:
                        21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. 2.In § 510.600, in the table in paragraph (c)(1), alphabetically add an entry for “Kindred Biosciences, Inc.” and remove the entry for “Piramal Healthcare Ltd.” and add an entry for “Piramal Enterprises Ltd.” in its place; and in the table in paragraph (c)(2), revise the entry for “065085” and numerically add an entry for “086078” to read as follows: § 510.600
  
 (c) * * * (1) * * * Firm name and address
Drug labeler code*         *         *         *         *         *         *Kindred Biosciences, Inc., 1555 Bayshore Hwy., Suite 200, Burlingame, CA 94010
086078*         *         *         *         *         *         *Piramal Enterprises Ltd., Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Mag Kurla (West), Mumbai, 400070, India
065085*         *         *         *         *         *         *
 (2) * * * Drug labeler 
                                     code
Firm name and address*         *         *         *         *         *         *065085
Piramal Enterprises Ltd., Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Mag Kurla (West), Mumbai, 400070, India.*         *         *         *         *         *         *086078
Kindred Biosciences, Inc., 1555 Bayshore Hwy., Suite 200, Burlingame, CA 94010.*         *         *         *         *         *         *
 PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
 3.The authority citation for part 520 continues to read as follows: Authority:
                        21 U.S.C. 360b. § 520.88f
 4.In § 520.88f, in paragraph (c)(2), remove “lacerations) due to *S. aureus, Streptococcus*
                         spp., 
                        *E. coli*
                        ” and in its place add “lacerations) due to 
                        *S. aureus, Enterococcus faecalis, E. coli*
                        ”. § 520.816
 5.In § 520.816, in paragraph (b), remove “050604” and in its place add “054771”. 6.Add § 520.2335 to read as follows: § 520.2335
  (a) 
                            *Specifications.*
                             Each milliliter of solution contains 10 milligrams (mg) telmisartan. (b) 
                            *Sponsor.*
                             See No. 000010 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use*
                            —(1) 
                            *Amount.*
                             Administer 1.5 mg/kilogram (kg) (0.68 mg/pound (lb)) orally twice daily for 14 days, followed by 2 mg/kg (0.91 mg/lb) orally once daily. (2) 
                            *Indications for use.*
                             For the control of systemic hypertension in cats. (3) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
 7.The authority citation for part 522 continues to read as follows: Authority:
                        21 U.S.C. 360b. 8.Revise § 522.1077 to read as follows: § 522.1077
  (a) 
                            *Specifications.*
                             Each milliliter (mL) of solution contains: (1) 43 micrograms (μg) of gonadorelin as gonadorelin acetate; (2) 100 μg of gonadorelin as gonadorelin acetate; (3) 43 μg of gonadorelin as gonadorelin diacetate tetrahydrate; or (4) 50 μg of gonadorelin as gonadorelin hydrochloride. (b) 
                            *Sponsors.*
                             See sponsor numbers in § 510.600(c) of this chapter. (1) No. 000061 for use of the 43-μg/mL product described in paragraph (a)(1) as in paragraphs (d)(1)(i), (d)(1)(iv), and (d)(2) of this section. (2) No. 068504 for use of the 100-μg/mL product described in paragraph (a)(2) as in paragraphs (d)(1)(ii), (d)(1)(v), and (d)(2) of this section. (3) No. 061623 for use of the 43-μg/mL product described in paragraph (a)(3) as in paragraphs (d)(1)(i) and (d)(2) of this section. (4) No. 050604 for use of the 43-μg/mL product described in paragraph (a)(3) as in paragraphs (d)(1)(i), (d)(1)(vi), and (d)(2) of this section. (5) No. 054771 for use of the 50-μg/mL product described in paragraph (a)(4) as in paragraphs (d)(1)(iii), (d)(1)(vii), and (d)(2) of this section. (c) 
                            *Special considerations.*
                             Concurrent luteolytic drug use is approved as follows: (1) Cloprostenol injection for use as in paragraph (d)(1)(iv) of this section as provided by No. 000061 in § 510.600(c) of this chapter. (2) Cloprostenol injection for use as in paragraph (d)(1)(v) and (d)(1)(vi) of this section as provided by No. 000061 or No. 068504 in § 510.600(c) of this chapter. (3) Dinoprost injection for use as in paragraph (d)(1)(vii) of this section as provided by No. 054771 in § 510.600(c) of this chapter. (d) 
                            *Conditions of use in cattle*
                            —(1) 
                            *Indications for use and amounts—*
                            (i) For the treatment of ovarian follicular cysts in dairy cattle: Administer 86 μg gonadorelin (No. 000061) or 100 μg gonadorelin diacetate tetrahydrate (Nos. 061623 and 050604) by intramuscular or intravenous injection. (ii) For the treatment of ovarian follicular cysts in dairy cattle: Administer 100 μg gonadorelin by intramuscular or intravenous injection. (iii) For the treatment of ovarian follicular cysts in cattle: Administer 100 μg gonadorelin by intramuscular injection. (iv) For use with cloprostenol injection to synchronize estrous cycles to allow for fixed-time artificial insemination (FTAI) in lactating dairy cows: Administer to each cow 86 μg gonadorelin by intramuscular injection, followed 6 to 8 days later by 500 μg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 86 μg gonadorelin by intramuscular injection. (v) For use with cloprostenol sodium to synchronize estrous cycles to allow for fixed-time artificial insemination (FTAI) in lactating dairy cows and beef cows: Administer to each cow 100 μg gonadorelin by intramuscular injection, followed 6 to 8 days later by 500 μg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 100 μg gonadorelin by intramuscular injection. (vi) For use with cloprostenol sodium to synchronize estrous cycles to allow for fixed-time artificial insemination (FTAI) in lactating dairy cows and beef cows: Administer to each cow 100 μg gonadorelin diacetate tetrahydrate by intramuscular injection, followed 6 to 8 days later by 500 μg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 100 μg gonadorelin diacetate tetrahydrate by intramuscular injection. (vii) For use with dinoprost injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows: Administer to each cow 100 to 200 μg gonadorelin by intramuscular injection, followed 6 to 8 days later by 25 mg dinoprost by intramuscular injection, followed 30 to 72 hours later by 100 to 200 μg gonadorelin by intramuscular injection. (2) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
 9.The authority citation for part 524 continues to read as follows: Authority:
                        21 U.S.C. 360b. 10.In § 524.957, revise paragraph (a) to read as follows: § 524.957
  (a) 
                            *Specifications.*
                             Each single-dose, prefilled dropperette contains 1 milliliter (mL) of a solution containing 16.6 milligrams (mg) florfenicol, 14.8 mg terbinafine (equivalent to 16.6 mg terbinafine hydrochloride), and 2.2 mg mometasone furoate.
 11.Add § 524.1448 to read as follows: § 524.1448
  (a) 
                            *Specifications.*
                             Each gram of ointment contains 20 milligrams (mg) mirtazapine. (b) 
                            *Sponsor.*
                             See No. 086078 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use*
                            —(1) 
                            *Amount.*
                             Administer topically by applying a 1.5 inch ribbon of ointment (approximately 2 mg) on the inner pinna of the cat's ear once daily for 14 days. Alternate the daily application of ointment between the left and right inner pinna of the ears. (2) 
                            *Indications for use.*
                             For the management of weight loss in cats. (3) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
 12.The authority citation for part 556 continues to read as follows: ( print page 64741)
                        Authority:
                        21 U.S.C. 342, 360b, 371. 13.In § 556.428, add paragraph (c) to read as follows: § 556.428
  
 (c) 
                            *Related conditions of use.*
                             See §§ 558.363 and 558.364 of this chapter.
 14.Revise § 556.445 to read as follows: § 556.445
  (a) [Reserved] (b) 
                            *Tolerances.*
                             A tolerance of 4 parts per million is established for residues of nicarbazin in uncooked chicken muscle, liver, skin, and kidney. (c) 
                            *Related conditions of use.*
                             See §§ 558.364 and 558.366 of this chapter.
 PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
 15.The authority citation for part 558 continues to read as follows: Authority:
                        21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371. 16.In § 558.68, revise paragraph (e)(1)(ii) and add paragraph (e)(1)(v) to read as follows: § 558.68
  
 (e) * * * (1) * * * Avilamycin in 
                                     grams/ton
Combination 
                                     in grams/ton
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(ii) 13.6 to 40.9
Monensin, 90 to 110
Broiler chickens: For the prevention of mortality caused by necrotic enteritis associated with 
                                    *Clostridium perfringens;*
                                     and as an aid in the prevention of coccidiosis caused by 
                                    *Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati,*
                                     and
                                    *E. maxima*
Feed as the sole ration for 21 consecutive days. To assure responsible antimicrobial drug use in broiler chickens, treatment administration must begin on or before 10 days of age. See § 558.355(d) of this chapter. Monensin as provided by No. 058198 in § 510.600(c) of this chapter
058198*         *         *         *         *         *         *(v) 13.6 to 40.9
Salinomycin sodium, 40 to 60
Broiler chickens: For the prevention of mortality caused by necrotic enteritis associated with 
                                    *Clostridium perfringens;*
                                     and for the prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti,*
                                     and
                                    *E. mivati*
Feed as the sole ration for 21 consecutive days. Feed to chickens that are at risk of developing, but not yet showing clinical signs of, necrotic enteritis associated with 
                                    *Clostridium perfringens.*
                                     Not approved for use with pellet binders. To assure responsible antimicrobial drug use in broiler chickens, treatment administration must begin on or before 10 days of age. The safety of avilamycin has not been established in chickens intended for breeding purposes. Avilamycin has not been demonstrated to be effective in broiler chickens showing clinical signs of necrotic enteritis prior to the start of medication. Do not feed to laying hens producing eggs for human consumption. May be fatal if fed to adult turkeys or to horses. Salinomycin as provided by No. 016592 in § 510.600(c) of this chapter
058198
 17.In § 558.76, remove and reserve paragraph (e)(1)(viii); redesignate paragraphs (e)(2)(xiii) through (xvii) as paragraphs (e)(2)(xiv) through (xviii); add new paragraph (e)(2)(xiii); and revise newly redesignated paragraph (e)(2)(xiv). The addition and revision read as follows: § 558.76
  
 (e) * * * (2) * * * (xiii) Narasin and nicarbazin as in § 558.364. (xiv) Nicarbazin as in § 558.366.
 18.In § 558.78, add paragraph (d)(3)(vii) to read as follows: § 558.78
  
 (d) * * * (3) * * * (vii) Nicarbazin as in § 558.366.
 19.In § 558.95, revise paragraph (d)(5)(viii); redesignate paragraphs (d)(5)(ix) through (xi) as paragraphs (d)(5)(x) through (xii); and add new paragraph (d)(5)(ix). The revision and addition read as follows: § 558.95
  
 (d) * * * (5) * * * (viii) Narasin as in § 558.363. (ix) Narasin and nicarbazin as in § 558.364.
 § 558.128
 20.In § 558.128, in paragraph (e)(3)(iv), in the “Limitations” column, at the end of the second sentence, add “Chlortetracycline and bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter.” § 558.325
 21.In § 558.325, in paragraph (e)(1)(iv), in the “Combination in grams/ton” column, remove “Decoquinate, 2.72” and in its place add “Decoquinate, 27.2”. 22.Revise § 558.363 to read as follows: § 558.363
  (a) 
                            *Specifications.*
                             Type A medicated articles containing 36, 45, 54, 72, and 90 grams narasin per pound. (b) 
                            *Sponsor.*
                             See No. 058198 in § 510.600(c) of this chapter. (c) 
                            *Tolerances.*
                             See § 556.428 of this chapter. (d) 
                            *Special considerations.*
                             An expiration date of 2 months (8 weeks) is required for narasin Type C medicated swine feeds. (e) 
                            *Conditions of use.*
                             It is used as follows: (1) 
                            *Chickens*
                            —
                            ( print page 64742) Narasin
                                     grams/ton
Combination in grams/ton
Indications for use
Limitations
Sponsor(i) 54 to 90

Broiler chickens: For prevention of coccidiosis caused by 
                                    *Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati,*
                                     and 
                                    *E. maxima*
For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal
058198(ii) 54 to 72
Bacitracin methylenedisalicylate, 10 to 50
Broiler chickens: For prevention of coccidiosis caused by 
                                    *Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati,*
                                     and 
                                    *E. maxima,*
                                     and for increased rate of weight gain and improved feed efficiency
For broiler chickens only. Feed continuously as sole ration. Do not feed to laying hens. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
054771(iii) 54 to 72
Bacitracin zinc, 4 to 50
Broiler chickens: For prevention of coccidiosis caused by 
                                    *Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati,*
                                     and 
                                    *E. maxima,*
                                     and for increased rate of weight gain and improved feed efficiency
For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Bacitracin zinc as provided by No. 054771 in § 510.600(c) of this chapter
054771(iv) 54 to 72
Bambermycins, 1 to 2
Broiler chickens: For prevention of coccidiosis caused by 
                                    *Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati,*
                                     and
                                    *E. maxima,*
                                     and for increased rate of weight gain and improved feed efficiency
For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Bambermycins as provided by No. 016592 in § 510.600(c) of this chapter
016592
 (2) 
                            *Swine*
                            — Narasin
                                     grams/ton
Combination in grams/ton
Indications for use
Limitations
Sponsor(i) 13.6 to 27.2

Growing-finishing swine: For increased rate of weight gain when fed for at least 4 weeks
Feed continuously for at least 4 weeks to swine during the growing-finishing period as the sole ration. No increased benefit in rate of weight gain has been shown when narasin concentrations in the diet are greater than 13.6 g/ton. Effectiveness has not been demonstrated when fed for durations less than 4 weeks. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Not approved for use in breeding animals because safety and effectiveness have not been evaluated in these animals. Swine being fed with narasin should not have access to feeds containing pleuromutilins (
                                    *e.g.*, tiamulin) as adverse reactions may occur. If signs of toxicity occur, discontinue use
058198(ii) 18.1 to 27.2

Growing-finishing swine: For increased rate of weight gain and improved feed efficiency when fed for at least 4 weeks
Feed continuously for at least 4 weeks to swine during the growing-finishing period as the sole ration. No increased benefit in rate of weight gain has been shown when narasin concentrations in the diet are greater than 13.6 g/ton. Effectiveness has not been demonstrated when fed for durations less than 4 weeks. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Not approved for use in breeding animals because safety and effectiveness have not been evaluated in these animals. Swine being fed with narasin should not have access to feeds containing pleuromutilins (
                                    *e.g.*, tiamulin) as adverse reactions may occur. If signs of toxicity occur, discontinue use
058198
 (3) Narasin single-ingredient Type A medicated articles may also be used in combination with: (i) Avilamycin as in § 558.68. (ii) [Reserved]
 § 558.364
 23.Redesignate § 558.364 as § 558.365. 24.Add new § 558.364 to read as follows: § 558.364
  (a) 
                            *Specifications.*
                             A fixed-ratio, combination drug Type A medicated article containing 36 grams narasin and 36 grams nicarbazin per pound. (b) 
                            *Sponsor.*
                             See No. 058198 in § 510.600(c) of this chapter. (c) 
                            *Tolerances.*
                             See §§ 556.428 and 556.445 of this chapter. (d) 
                            *Conditions of use.*
                             It is used as follows: (1) 
                            *Chickens*
                            —
                            ( print page 64743) Narasin and
                                     nicarbazin 
                                     grams/ton
Combination in grams/ton
Indications for use
Limitations
Sponsor(i) 27 to 45 of each drug

Broiler chickens: For prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti,*
                                     and
                                    *E. mivati*
Feed continuously as sole ration. Do not feed to laying hens. Withdraw 5 days before slaughter. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal
058198(ii) 27 to 45 of each drug
Bacitracin methylenedisalicylate, 4 to 50
Broiler chickens: For prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti,*
                                     and
                                    *E. mivati,*
                                     and for increased rate of weight gain and improved feed efficiency
Feed continuously as sole ration. Do not feed to laying hens. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
058198(iii) 27 to 45 of each drug
Bacitracin methylenedisalicylate, 50
Broiler chickens: For prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti,*
                                     and
                                    *E. mivati,*
                                     and as an aid in the prevention of necrotic enteritis caused or complicated by 
                                    *Clostridium*
                                     spp. or other organisms susceptible to bacitracin
Feed continuously as sole ration. Withdraw 5 days before slaughter. Do not feed to laying hens. Do not allow turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
054771(iv) 27 to 45 of each drug
Bacitracin methylenedisalicylate, 100 to 200
Broiler chickens: For prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti,*
                                     and
                                    *E. mivati,*
                                     and as an aid in the control of necrotic enteritis caused or complicated by 
                                    *Clostridium*
                                     spp. or other organisms susceptible to bacitracin
To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 g/ton). Do not feed to laying hens. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
054771(v) 27 to 45 of each drug
Bambermycins, 1 to 2
Broiler chickens: As an aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima, E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis, and for increased rate of weight gain and improved feed efficiency
Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not feed to laying hens. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Bambermycins as provided by No. 016592 in § 510.600(c) of this chapter
058198
 (2) Narasin and nicarbazin fixed-ratio, combination drug Type A medicated articles may also be used in combination with: (i) Avilamycin as in § 558.68. (ii) [Reserved]
 25.Revise § 558.366 to read as follows: § 558.366
  (a) 
                            *Specifications.*
                             Type A medicated articles containing 25 percent nicarbazin. (b) 
                            *Sponsors.*
                             See Nos. 058198, 060728, and 066104 in § 510.600(c) of this chapter for use as in paragraph (d) of this section. (c) 
                            *Related tolerances.*
                             See § 556.445 of this chapter. (d) 
                            *Conditions of use.*
                             It is used as follows: (1) 
                            *Chickens—* Nicarbazin in
                                     grams per ton
Combination
                                     in grams per ton
Indications for use
Limitations
Sponsor(i) 90.8 to 181.6

Broiler chickens: As an aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima,**E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis
Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for outbreaks of coccidiosis. Do not use in flushing mashes. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton
066104(ii) 90.8 to 181.6
Bacitracin methylenedisalicylate, 4 to 50
Broiler chickens: As an aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima, E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis, and for increased rate of weight gain and improved feed efficiency
Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for outbreaks of coccidiosis. Do not use in flushing mashes. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Nicarbazin as provided by No. 066104; bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
054771( print page 64744)(iii) 90.8 to 181.6
Bacitracin methylenedisalicylate, 30
Broiler chickens; As an aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima, E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis, and for increased rate of weight gain and improved feed efficiency
Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not use in flushing mashes. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Nicarbazin as provided by No. 066104; bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
066104(iv) 90.8 to 181.6
Bacitracin methylenedisalicylate 50
Broiler chickens: As an aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima, E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis, and as an aid in the prevention of necrotic enteritis caused or complicated by 
                                    *Clostridium*
                                     spp. or other organisms susceptible to bacitracin
Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for outbreaks of coccidiosis. Do not use in flushing mashes. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Nicarbazin as provided by No. 066104; bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
054771(v) 113.5

Chickens: As an aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima, E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis
Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not use in flushing mashes. Do not feed to laying hens. Withdraw 4 days before slaughter
058198
                                     060728(vi) 113.5
Bacitracin methylenedisalicylate, 30
Broiler chickens; aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima, E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis, and for increased rate of weight gain and improved feed efficiency
Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not use in flushing mashes. Do not feed to laying hens. Withdraw 4 days before slaughter. Nicarbazin as provided by No. 066104; bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
060728(vii) 113.5
Bacitracin zinc, 4 to 50
Broiler chickens; aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima, E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis, and for increased rate of weight gain and improved feed efficiency
For broiler chickens only. Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use in flushing mashes. Do not feed to laying hens. Withdraw 4 days before slaughter. Nicarbazin as provided by No. 066104, bacitracin zinc as provided by No. 054771 in § 510.600(c) of this chapter
054771
                                     066104(viii) 113.5
Bambermycins, 1 to 2
Broiler chickens: As an aid in preventing outbreaks of cecal (
                                    *Eimeria tenella*) and intestinal (
                                    *E. acervulina, E. maxima, E. necatrix,*
                                     and 
                                    *E. brunetti*) coccidiosis, and for increased rate of weight gain and improved feed efficiency
Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis. Do not use in flushing mashes. Do not feed to laying hens. Withdraw 4 days before slaughter. Nicarbazin as provided by No. 066104; bambermycins as provided by No. 016592 in § 510.600(c) of this chapter
016592
 (2) [Reserved]
 § 558.485
 26.In § 558.485, in paragraph (e)(2), in the “Limitations” column, remove “Not for use in horses intended for food.” and in its place add “Do not use in horses intended for human consumption.” Dated: December 11, 2018. Leslie Kux, Associate Commissioner for Policy.


[FR Doc. 2018-27238 Filed 12-17-18; 8:45 am] BILLING CODE 4164-01-P